Solomon Woldu, MD
Urology · Dallas, TXNPI 1518284462
Payments from drug & device makers
Across 175 payments — averaging $7071.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.2M
- Urogen Pharma, Inc.$41K
- Ferring Pharmaceuticals AS$19K
- Organon$3K
- Photocure Inc$850
- Johnson & Johnson$737
- plus $6K from 31 others
Across 4 payments — averaging $2122.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urogen Pharma, Inc.$8K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 59 | $1,167,174 |
| Urogen Pharma, Inc. | 25 | $40,887 |
| Ferring Pharmaceuticals AS | 8 | $18,665 |
| Organon | 2 | $2,995 |
| Photocure Inc | 9 | $850 |
| Johnson & Johnson(2 entities) | 7 | $737 |
| AstraZeneca | 6 | $698 |
| Myriad Genetic Laboratories, Inc. | 3 | $489 |
| Conmed Corporation | 3 | $389 |
| Dendreon Pharmaceuticals LLC | 3 | $388 |
| Intuitive Surgical | 6 | $364 |
| Biotissue Holdings Inc. | 1 | $361 |
| Blue Earth Diagnostics | 3 | $335 |
| KARL Storz Endoscopy-america | 5 | $311 |
| Profound Medical Corp. | 2 | $304 |
| Novartis | 2 | $276 |
| Boston Scientific | 3 | $267 |
| Foundation Medicine, Inc. | 3 | $198 |
| Medtronic | 2 | $175 |
| Olympus America Inc. | 3 | $166 |
| Immunitybio, Inc. | 1 | $150 |
| Janssen Scientific Affairs, LLC | 1 | $140 |
| Sumitomo Pharma America, Inc. | 1 | $134 |
| Clovis Oncology, Inc. | 1 | $133 |
| AVEO Pharmaceuticals, Inc. | 1 | $132 |
| Myovant Sciences Inc. | 1 | $122 |
| Procept Biorobotics Corporation | 1 | $109 |
| Progenics Pharmaceuticals, Inc. | 1 | $107 |
| Bayer | 1 | $106 |
| Astellas Pharma US Inc | 1 | $104 |
| EMD Serono, Inc. | 1 | $95 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $78 |
| 180 Medical, Inc. | 2 | $39 |
| Convatec Inc. | 2 | $39 |
| Ferring Pharmaceuticals Inc. | 1 | $26 |
| Tempus AI, Inc | 1 | $24 |
| Halozyme Inc | 1 | $16 |
How this compares
$1,237,583 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other urology in Dallas
- Homa PorterDallas$1.8M
- Vitaly MargulisDallas$1.8M
- James CochranDallas$1.1M
- Yair LotanDallas$1.1M
- Allen MoreyDallas$1M
- Claus RoehrbornDallas$292K
- Brett JohnsonDallas$175K
- Pat FulghamDallas$174K
- Gregory ThoresonDallas$162K
- Zvi SchiffmanHouston$17.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.